AUSTIN, TEXAS--(BUSINESS WIRE)--
Altogen Labs, a GLP-compliant contract research laboratory (CRO), offers in vivo xenograft efficacy studies and pharmacology/toxicology services designed to accelerate preclinical research and drug development. Cancer pathologies without a therapeutic solution have unfortunately not disappeared in the context of the global COVID-19 crisis. Altogen Labs remains operational and we are adapting to developments as they occur.
Altogen Labs provides over 90 in-house xenograft models to accelerate the development of novel anti-cancer medicines, treat inflammation, infectious diseases, immunology and obesity. Altogen Labs scientists perform a variety of acute, sub-chronic and chronic toxicity tests for assessing drug toxicity and also provide a comprehensive statistical and quantitative analysis for the investigation of toxic effects of potential drug candidates. Acute toxicology studies analyze short-term toxicological effects after a single large dose of a tested compound. During sub-chronic toxicology studies, Altogen Labs scientists determine the toxicity of chemical substances after repeated administration of small doses of the test substance after a time period of 3 months. Chronic toxicity tests examine the compound's adverse effects following prolonged and repeated exposure of several months to a year or longer.
The identification of possible adverse effects is critical in achieving clinical efficacy and safety in humans. In vivo efficacy (90+ xenograft models) and safety (toxicology) studies evaluate various dosage levels and routes of drug administration to optimize an investigational new drug (IND) delivery and biodistribution. Altogen Labs offers a variety of in vivo services for efficacy studies in the preclinical drug discovery phase, including teratoma formation services, murine xenograft models for cancer, pharmacokinetics (PK) and pharmacodynamics (PD) services. Preclinical toxicology studies determine the toxicity of the test compound and evaluate the therapeutic effectiveness of a potential drug candidate prior to initiating clinical trials.
About Altogen Labs
Altogen Labs (altogenlabs.com) is a GLP-compliant contract research organization (CRO), headquartered in Austin, Texas (USA) that provides a multitude of biotechnology and preclinical pharmacology services. Altogen Labs primarily focuses on cancer research, drug development and associated oncology CRO research services, including biodistribution research studies, toxicology IND studies, gene function and gene expression analysis, in vivo RNAi and tissue-targeted siRNA delivery services, and development of stable cell lines.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200519005303/en/
Copyright Business Wire 2020